Riskpilot← Back to searchSign inGet full accessMKL Diagnostics AB
ABDissolvedOrg 5568703473Manufacture of other chemical products n.e.c. · NACE 2059Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
+113% vs 2023
Equity ratio
91.8%
Financial strength
Net profit 2024
SEK 1,2M
+7012% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 1,5M | +113% |
| Net profit | SEK 1,2M | +7012% |
| Total assets | SEK 4,2M | -14% |
| Equity | SEK 3,9M | +46% |
| Employees | 0 | — |
Legal name
MKL Diagnostics AB
Org number
5568703473
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
2 november 2011
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva utveckling, produktion och försäljning av reagens för mikrobiologiska analyser, diagnostiska produkter samt läkemedel och läkemedelsnära produkter samt bedriva därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 689 | 1 819 | 399 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 811 | −7 458 | −11 187 | −11 955 | 1 539 |
| Depreciation & amort. | −10 | −14 | −14 | −14 | −14 |
| EBIT | −6 821 | −7 472 | −11 201 | −11 969 | 1 525 |
| Net financials | 13 | 5 | — | — | — |
| Profit before tax | 1 692 | 533 | 298 | 30 | 1 525 |
| Tax | −296 | −123 | −66 | −13 | −316 |
| Net profit | 1 396 | 410 | 232 | 17 | 1 209 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 060 | 3 640 | 3 971 | 4 873 | 4 206 |
| Equity | 1 993 | 2 403 | 2 635 | 2 652 | 3 862 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 066 | 1 237 | 1 336 | 2 221 | 344 |
| Total debt | 1 066 | 1 237 | 1 336 | 2 221 | 344 |
EBITDA margin
153900000.0%
This company
15.8%
Market median
+974050533% vs market
20202024
Equity ratio
91.8%
This company
38.2%
Market median
+140% vs market
20202024
Return on equity
31.3%
This company
18.4%
Market median
+70% vs market
20202024
Net profit margin
120900000.0%
This company
8.1%
Market median
+1492592493% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-01-01 – 2020-03-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BF Chief Executive Officer | Chief Executive Officer | 2022 |
JH | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AUSTRALIAN LABORATORY SERVICES PTY LTDAls Scandinavia AktiebolagMikrolab Stockholm AB
MKL Diagnostics AB (this company)Board members of MKL Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Fredrik Johansson | Chief Executive Officer | 0 companies |
| Jesper Hans Fredrik Eriksson | Audit | 0 companies |
| Per Andreas Jonsson | Chairman | 0 companies |
| Martin Leonard Stener | Deputy Board Member | 0 companies |